PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS
Methods, compositions, and uses for pre-treating patients who are susceptible to ischemia, including stroke, with nitroxides, in order to prevent or ameliorate the effects of stroke or other ischemic disease.
1 . A method of treatment, comprising:
identifying a human patient that is susceptible to ischemia; and
reducing the likelihood of an occurrence of a harmful effect of ischemia by administering an effective amount of a stable free radical prior to the onset of ischemia;
wherein the likelihood is reduced in comparison to a human patient that was not subjected to the administering step.
2 . The method of claim 1 , wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
3 . The method of claim 1 , wherein the human patient's susceptibility to ischemia arises from a medical procedure associated with a significant ischemic risk.
4 . The method of claim 3 , wherein the medical procedure is the treatment of a hemorrhage.
5 . The method of claim 3 , wherein the medical procedure is the treatment of an aneurysm.
6 . The method of claim 3 , wherein the medical procedure is surgery.
7 . The method of claim 3 , wherein the medical procedure is an endovascular procedure.
8 . The method of claim 1 , wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
9 . A method of treatment comprising:
identifying a patient scheduled to undergo a medical procedure involving a risk of ischemia;
reducing the likelihood of an occurrence of a harmful effect of ischemia by administering to the patient, prior to the medical procedure, an effective amount of a stable free radical nitroxide;
performing the medical procedure; and
administering to the patient, an additional amount of a stable free radical nitroxide to ameliorate a harmful effect of ischemia.
10 . The method of claim 9 , wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
11 . The method of claim 9 , wherein the medical procedure is the treatment of a hemorrhage.
12 . The method of claim 9 , wherein the medical procedure is the treatment of an aneurysm.
13 . The method of claim 9 , wherein the medical procedure is surgery.
14 . The method of claim 9 , wherein the medical procedure is an endovascular procedure.
15 . The method of claim 9 , wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
16 . The method of claim 1 wherein the nitroxide is selected from the group consisting of
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH2NH2;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocylohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is CONH;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is H, OH, and NH 2 ;
wherein R 1 is —CH 3 ; R 2 is —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —C 6 H 13 , —CH 2 —CH(CH 3 ) 2 , —CHCH 3 C 2 H 5 , or —(CH 2 ) 7 —CH 3 , or wherein R 1 and R 2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane; R 3 is —O. or —OH, or a physiologically acceptable salt thereof which has antioxidant activity;
wherein R 3 is —O. or —OH; and
wherein R 4 and R 5 combine together with the nitrogen to form a heterocyclic group; wherein the atoms in the heterocyclic group (other than the N atom shown in the formula) may be all C atoms or may be C atoms and one or more N, O and/or S atoms; or
wherein R 4 and R 5 combine together to form substituted or unsubstituted pyrrole, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, or purine; or
wherein R 4 and R 5 themselves comprise a substituted or unsubstituted cyclic or heterocyclic group;
2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl, 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempamine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, 4-oxo-TEMPO, 4-amino-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-(ethoxyfluorophosphonyloxy)-TEMPO, 4-hydroxy-TEMPO, 4-(2-iodo acetamido)-TEMPO, 4-isothiocyanato-TEMPO, 4-maleimido-TEMPO, 4-(4-nitrobenzoyloxyl)-TEMPO, and 4-phosphonooxy-TEMPO.
17 . The method of claim 9 wherein the nitroxide is selected from the group consisting of
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH2NH2;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocylohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is CONH;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 ;
wherein R 1 is —CH 3 ; R 2 is —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —C 6 H 13 , —CH 2 —CH(CH 3 ) 2 , —CHCH 3 C 2 H 5 , or —(CH 2 ) 7 —CH 3 , or wherein R 1 and R 2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane; R 3 is —O. or —OH, or a physiologically acceptable salt thereof which has antioxidant activity;
wherein R 3 is —O. or —OH; and
wherein R 4 and R 5 combine together with the nitrogen to form a heterocyclic group; wherein the atoms in the heterocyclic group (other than the N atom shown in the formula) may be all C atoms or may be C atoms and one or more N, O and/or S atoms; or
wherein R 4 and R 5 combine together to form substituted or unsubstituted pyrrole, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, or purine; or
wherein R 4 and R 5 themselves comprise a substituted or unsubstituted cyclic or heterocyclic group;
2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl, 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempamine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, 4-oxo-TEMPO, 4-amino-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-(ethoxyfluorophosphonyloxy)-TEMPO, 4-hydroxy-TEMPO, 4-(2-iodo acetamido)-TEMPO, 4-isothiocyanato-TEMPO, 4-maleimido-TEMPO, 4-(4-nitrobenzoyloxyl)-TEMPO, and 4-phosphonooxy-TEMPO.
18 . A method of treatment comprising:
identifying a human patient who is susceptible to ischemia associated with a medical procedure; and
reducing a harmful effect of ischemia in the human patient after the medical procedure by administering an effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl prior to the onset of ischemia and prior to the medical procedure.
19 . The method of claim 18 , wherein the human patient's susceptibility to ischemia arises from a medical procedure associated with a significant ischemic risk.
20 . The method of claim 18 , wherein the medical procedure is the treatment of a hemorrhage.
21 . The method of claim 18 , wherein the medical procedure is the treatment of an aneurysm.
22 . The method of claim 18 , wherein the medical procedure is surgery.
23 . The method of claim 18 , wherein the medical procedure is an endovascular procedure.
24 . The method of claim 18 , wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
25 . A method of treatment comprising:
identifying a patient scheduled to undergo a medical procedure involving a significant risk of ischemia;
reducing a harmful effect of ischemia in the human patient after the medical procedure by administering an effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl performing the medical procedure; and
administering to the patient after the performing step, an additional amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl effective to reduce a harmful effect of ischemia
26 . The method of claim 25 , wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
27 . The method of claim 25 , wherein the medical procedure is the treatment of a hemorrhage.
28 . The method of claim 25 , wherein the medical procedure is the treatment of an aneurysm.
29 . The method of claim 25 , wherein the medical procedure is surgery.
30 . The method of claim 25 , wherein the medical procedure is an endovascular procedure.